WASHINGTON: In 4Q16, AstraZeneca (AZN) reported a 12% decline in revenues at constant exchange rates to ~$5.6 billion. This included a 15% decline in product sales to ~$5.3 billion, as well as 77% growth in externalization revenues to $325 million during 4Q16, compared to 4Q15.
At constant exchange rates, the decline in revenues included an 8% decline in product sales to ~$21.3 billion, partially offset by ~59% growth in externalization revenues to ~$1.7 billion during fiscal 2016. The above graph shows AstraZeneca’s revenues in each quarter of 2015 and 2016. The company has operations in over 100 countries, and ~64% of its total revenues are reported from its sales outside the US markets. As a result, the company is substantially exposed to currency risk.
